• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Transcode Therapeutics Inc (NQ: RNAZ )

    0.8734 +0.0034 (+0.39%)
    Streaming Delayed Price Updated: 1:42 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Transcode Therapeutics Inc

    < Previous 1 2 3 Next >
    Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
    TransCode shares to remain listed on Nasdaq 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Open Letter to Shareholders
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
    Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports 2023 Results; Provides Business Update
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
    Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
    Highlights TTX-MC138’s Path from Target Discovery to the Clinic 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
    Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
    Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic... 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
    TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Withdraws Public Offering
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Public Offering of Common Stock
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
    Suggests potential to improve survival outcomes in patients with GBM 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
    Evidence of Drug Accumulation in Metastatic Lesions 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
    Study showed a 70% Inhibition of Recurrent Tumor Growth 
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    TransCode Therapeutics Announces Pricing of $8 Million Public Offering
    From TransCode Therapeutics, Inc.
    Via GlobeNewswire
    Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.